We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mouse Explants Generated from Patients' Circulating Tumor Cells Pave Way for Directed Personalized Chemotherapy

By LabMedica International staff writers
Posted on 19 Jun 2014
Print article
Image: Histopathologic image of small-cell lung cancer (Photo courtesy of Wikimedia Commons).
Image: Histopathologic image of small-cell lung cancer (Photo courtesy of Wikimedia Commons).
Cancer researchers have isolated circulating tumor cells (CTCs) from patients with small-cell lung cancer (SCLC) and implanted them into immunocompromised mice to use as a model system for developing better treatments for the disease.

SCLC is an aggressive neuroendocrine tumor with early dissemination and poor prognosis that accounts for 15%–20% of lung cancer cases and approximately 200,000 deaths in the United Kingdom each year. Most cases are inoperable, and biopsies to investigate SCLC biology are rarely obtainable. A more promising approach for studying SCLC is by collecting "liquid biopsy" specimens—CTCs, which are prevalent in the blood of SCLC patients.

Investigators at the University of Manchester (United Kingdom) reported in June 1, 2014, online edition of the journal Nature Medicine that CTCs from SCLC patients who either responded to chemotherapy or failed to respond to chemotherapy developed into tumors in immunocompromised mice. The resultant CTC-derived explants (CDXs) mirrored the donor patient's response to platinum and etoposide chemotherapy. Genomic analysis of isolated CTCs revealed considerable similarity to the corresponding CDX.

Senior author Dr. Caroline Dive, professor of pharmacology and pharmacy at the University of Manchester, said, “Access to sufficient tumor tissue is a major barrier to fully understanding the biology of SCLC. This liquid biopsy is straightforward and not invasive so can be easily repeated and will allow us to study the genetics of each lung cancer patient’s individual tumor. It also means that we may have a feasible way of monitoring patient response to therapy, hopefully allowing us to personalize and tailor individual treatment plans to each patient. We can use these models to help us understand why so many SCLC patients acquire resistance to chemotherapy and to search for and test potential new targeted treatments.”

Related Links:

University of Manchester


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.